NO20084302L - 2-(syklisk amino)-pyrimidonderivater som TPK1-inhibitorer - Google Patents

2-(syklisk amino)-pyrimidonderivater som TPK1-inhibitorer

Info

Publication number
NO20084302L
NO20084302L NO20084302A NO20084302A NO20084302L NO 20084302 L NO20084302 L NO 20084302L NO 20084302 A NO20084302 A NO 20084302A NO 20084302 A NO20084302 A NO 20084302A NO 20084302 L NO20084302 L NO 20084302L
Authority
NO
Norway
Prior art keywords
hydrogen
cyclic amino
pyrimidone derivatives
integer
tpk1
Prior art date
Application number
NO20084302A
Other languages
English (en)
Inventor
Satoshi Yokoshima
Fumiaki Uehara
Kazutoshi Watanabe
Kenji Fukunaga
Toshiyuki Kohara
Yoshihiro Usul
Daiki Sakai
Shi-Ichi Kusaka
Kazuki Nakayama
Original Assignee
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tanabe Pharma Corp filed Critical Mitsubishi Tanabe Pharma Corp
Publication of NO20084302L publication Critical patent/NO20084302L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/06—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing isoquinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Forbindelse representert ved formel en optisk aktiv isomer derav, eller et farmasøytisk akseptabelt salt derav, hvor R2 er hydrogen eller lignende; R3 er metyl eller lignende; R20 er halogen eller lignende; q er et helt tall fra 0 til 3; Z er nitrogen, CH eller lignende; R4 er hydrogen eller lignende; R5 er hydrogen eller lignende; R6 er substituert alkyloksy eller lignende; p er et helt tall fra 0 til 3; X representerer en binding, CH2, oksygenatom, NH eller lignende; hvilke som helst av R5 og R6, R5 og R4, R6 og R4, X og R5, X og R4, X og R6 og R6 og R6 kan være kombinert med hverandre og danne en ring. Forbindelsen anvendes til forebyggende og/eller terapeutisk behandling av en sykdom forårsaket av t-proteinkinase 1-hyperaktivitet, så som neurodegenerative sykdommer (f.eks. Alzheimers sykdom).
NO20084302A 2006-03-15 2008-10-14 2-(syklisk amino)-pyrimidonderivater som TPK1-inhibitorer NO20084302L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006110242 2006-03-15
PCT/JP2007/055787 WO2007119463A1 (en) 2006-03-15 2007-03-14 2-(cyclic amino)-pyrimidone derivatives as tpk1 inhibitors

Publications (1)

Publication Number Publication Date
NO20084302L true NO20084302L (no) 2008-12-03

Family

ID=38110618

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20084302A NO20084302L (no) 2006-03-15 2008-10-14 2-(syklisk amino)-pyrimidonderivater som TPK1-inhibitorer

Country Status (16)

Country Link
US (1) US8569294B2 (no)
EP (2) EP2001863A1 (no)
JP (2) JP2009530229A (no)
KR (1) KR20080102430A (no)
CN (1) CN101400668A (no)
AR (1) AR059899A1 (no)
AU (1) AU2007239962A1 (no)
BR (1) BRPI0708914A2 (no)
CA (1) CA2644979A1 (no)
EA (1) EA200870358A1 (no)
MX (1) MX2008011780A (no)
NO (1) NO20084302L (no)
NZ (1) NZ571709A (no)
TW (1) TW200813015A (no)
WO (1) WO2007119463A1 (no)
ZA (1) ZA200808364B (no)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200813015A (en) * 2006-03-15 2008-03-16 Mitsubishi Pharma Corp 2-(cyclic amino)-pyrimidone derivatives
AR064660A1 (es) * 2006-12-26 2009-04-15 Mitsubishi Tanabe Pharma Corp Derivados de pirimidinona 6-heterociclica 2-sustituida, medicamentos que los contienen y usos para prevenir y/o tratar enfermedades neurodegenerativas entre otras
AU2008297817A1 (en) 2007-09-14 2009-03-19 Mitsubishi Tanabe Pharma Corporation 6-pyrimidinyl-pyrimid-4-one derivative
EP2078717A1 (en) * 2008-01-11 2009-07-15 sanofi-aventis 6-Pyrimidinyl-pyrimid-2-one derivative
CN101538222B (zh) * 2008-03-18 2012-12-26 上海医药工业研究院 N-(2-苯基)乙基-2-[(2,2-二甲氧乙基)氨基]乙酰胺卤酸盐的制备方法
CN102300462B (zh) * 2008-12-03 2015-01-28 普雷西迪奥制药公司 Hcv ns5a的抑制剂
AR076014A1 (es) * 2009-04-02 2011-05-11 Sanofi Aventis Derivados de 3- (1,4) oxazepan -4-pirimidona
US9006232B2 (en) 2009-08-13 2015-04-14 Mitsubishi Tanabe Pharma Corporation Pyrimidone derivatives
US8940738B2 (en) 2009-08-13 2015-01-27 Mitsubishi Tanabe Pharma Corporation Pyrimidone compounds
EP2479165B1 (en) 2009-09-16 2017-10-25 Astellas Pharma Inc. Glycine compound
EP2683700B1 (de) 2011-03-08 2015-02-18 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8901114B2 (en) 2011-03-08 2014-12-02 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
EP2683705B1 (de) 2011-03-08 2015-04-22 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CN103232356B (zh) * 2013-05-15 2017-02-15 天津金族科技有限公司 一种制备3‑苯基‑4‑氨基丁酸盐酸盐的工艺
EP3119774A1 (en) * 2014-03-17 2017-01-25 reMynd NV Oxadiazole compounds
WO2016030306A1 (en) * 2014-08-27 2016-03-03 F. Hoffmann-La Roche Ag Substituted pyrazino[2,1-a]isoquinoline derivatives for the treatment of cns disorders
CN104193695B (zh) * 2014-09-03 2016-06-22 哈尔滨工业大学 一种吗啡啉类化合物的合成方法
WO2016179059A1 (en) * 2015-05-05 2016-11-10 Merck Sharp & Dohme Corp. Heteroaryl-pyrimidinone compounds as pde2 inhibitors
EP3319968A1 (en) 2015-07-06 2018-05-16 Rodin Therapeutics, Inc. Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
RS62639B1 (sr) 2015-07-06 2021-12-31 Alkermes Inc Hetero-halo inhibitori histonskih deacetilaza
CA3049443A1 (en) 2017-01-11 2018-07-19 Rodin Therapeutics, Inc. Bicyclic inhibitors of histone deacetylase
US11225475B2 (en) 2017-08-07 2022-01-18 Alkermes, Inc. Substituted pyridines as inhibitors of histone deacetylase
CN107602457A (zh) * 2017-10-10 2018-01-19 重庆奥舍生物化工有限公司 一锅法合成6‑甲基‑2‑氨基‑异烟酸的方法
KR101957063B1 (ko) 2017-12-27 2019-03-11 주식회사 비케이에스 유압브레이커의 스텝씰
BR112020018444A2 (pt) * 2018-03-14 2020-12-29 Fochon Pharmaceuticals, Ltd. Compostos de (2-azabiciclo[3,1,0]hexan-2-il)pirazolo[1,5-a]pirimidina substituída e imidazo[1,2-b]piridazina como inibidores de trk cinases
US11878018B1 (en) * 2018-12-20 2024-01-23 Unm Rainforest Innovations Phosphorylation of Syntaxin 17 by TBK1 controls autophagy initiation
WO2020210785A1 (en) * 2019-04-12 2020-10-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services D3 receptor agonist compounds; methods of preparation; intermediates thereof; and methods of use thereof
CN113912622B (zh) * 2020-07-10 2023-12-01 上海纽思克生物科技有限公司 三环嘧啶酮类化合物、其制备方法、其组合物和用途
CN111978242B (zh) * 2020-08-21 2023-09-26 上海科利生物医药有限公司 一种(r)-3-氨基哌啶二盐酸盐的制备方法及应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4935634B1 (no) * 1970-12-30 1974-09-25
JPS5124008B2 (no) 1972-08-10 1976-07-21
US5140029A (en) 1989-01-09 1992-08-18 Janssen Pharmaceutica N.V. 2-aminopyrimidinone derivatives
US5256659A (en) 1989-01-09 1993-10-26 Janssen Pharmaceutica N.V. 2-aminopyrimidinone derivatives
GB8900382D0 (en) 1989-01-09 1989-03-08 Janssen Pharmaceutica Nv 2-aminopyrimidinone derivatives
CA2116460A1 (en) 1993-03-02 1994-09-03 Mitsubishi Chemical Corporation Preventive or therapeutic agents for alzheimer's disease, a screening method of alzheimer's disease and tau-protein kinase i originated from human being
US6410729B1 (en) * 1996-12-05 2002-06-25 Amgen Inc. Substituted pyrimidine compounds and methods of use
AR023052A1 (es) 1998-09-25 2002-09-04 Mitsuharu Yoshimura Milton Derivados de pirimidona
WO2001070728A1 (en) * 2000-03-23 2001-09-27 Sanofi-Synthelabo 2-[nitrogen-heterocyclic]pyrimidone derivatives
EP1136482A1 (en) 2000-03-23 2001-09-26 Sanofi-Synthelabo 2-Amino-3-(alkyl)-pyrimidone derivatives as GSK3beta inhibitors
EP1136493A1 (en) * 2000-03-23 2001-09-26 Sanofi-Synthelabo 2-(Thienopyridinyl)pyrimidone, 2-(furopyridinyl)pyrimidone 2-(isoquinolinyl)pyrimidone, 2-(pyridoindolyl)pyrimidone and 2-(benzofuropyridinyl)pyrimidone derivatives
JP4368682B2 (ja) * 2001-09-21 2009-11-18 田辺三菱製薬株式会社 ３−置換−４−ピリミドン誘導体
WO2003037888A1 (en) * 2001-09-21 2003-05-08 Mitsubishi Pharma Corporation 3-substituted-4-pyrimidone derivatives
ZA200505258B (en) * 2002-12-16 2006-09-27 Mitsubishi Pharma Corp 3-Substituted-4-pyrimidone derivatives
EP1454910A1 (en) * 2003-03-07 2004-09-08 Sanofi-Synthelabo Substituted pyrimidinyl-2-(diaza-bicyclo-alkyl)-pyrimidone derivatives
BRPI0408186A (pt) 2003-03-07 2006-04-04 Sanofi Aventis derivados de 2-(diaza-biciclo-alquil)-pirimidona substituìdos
TWI357408B (en) * 2003-03-26 2012-02-01 Mitsubishi Tanabe Pharma Corp 3-substituted-4-pyrimidone derivatives
US7582631B2 (en) 2004-01-14 2009-09-01 Amgen Inc. Substituted heterocyclic compounds and methods of use
AR050865A1 (es) * 2004-09-09 2006-11-29 Sanofi Aventis Derivados de 2- morfolino-4-pirimidona
ZA200703383B (en) * 2004-09-29 2009-05-27 Mitsubishi Pharma Corp 6-(pyridinyl)-4-pyrimidone derivates as tau protein kinase 1 inhibitors
TW200740779A (en) * 2005-07-22 2007-11-01 Mitsubishi Pharma Corp Intermediate compound for synthesizing pharmaceutical agent and production method thereof
TW200813015A (en) * 2006-03-15 2008-03-16 Mitsubishi Pharma Corp 2-(cyclic amino)-pyrimidone derivatives
AR064660A1 (es) * 2006-12-26 2009-04-15 Mitsubishi Tanabe Pharma Corp Derivados de pirimidinona 6-heterociclica 2-sustituida, medicamentos que los contienen y usos para prevenir y/o tratar enfermedades neurodegenerativas entre otras
CA2698818A1 (en) * 2007-09-14 2009-03-19 Sanofi-Aventis 3-methyl-2- ( (2s) -2- (4- (3-methyl-1, 2, 4-oxadiazol-5-yl) phenyl) morpholino) -6- (pyrimidin-4-yl) pyrimidin-4 (3h) -one as tau protein kinase inhibitor
AU2008297817A1 (en) * 2007-09-14 2009-03-19 Mitsubishi Tanabe Pharma Corporation 6-pyrimidinyl-pyrimid-4-one derivative
EP2078717A1 (en) 2008-01-11 2009-07-15 sanofi-aventis 6-Pyrimidinyl-pyrimid-2-one derivative
TW201043618A (en) * 2009-03-10 2010-12-16 Sanofi Aventis Intermediate compound for synthesizing pharmaceutical agent and production method thereof
US8940738B2 (en) * 2009-08-13 2015-01-27 Mitsubishi Tanabe Pharma Corporation Pyrimidone compounds

Also Published As

Publication number Publication date
NZ571709A (en) 2011-11-25
BRPI0708914A2 (pt) 2011-07-12
AR059899A1 (es) 2008-05-07
US20090233918A1 (en) 2009-09-17
EP2001863A1 (en) 2008-12-17
EP2423207A2 (en) 2012-02-29
TW200813015A (en) 2008-03-16
EP2423207A3 (en) 2012-06-13
CN101400668A (zh) 2009-04-01
JP2009530229A (ja) 2009-08-27
JP2015078216A (ja) 2015-04-23
AU2007239962A1 (en) 2007-10-25
WO2007119463A1 (en) 2007-10-25
CA2644979A1 (en) 2007-10-25
EA200870358A1 (ru) 2009-02-27
MX2008011780A (es) 2008-12-03
ZA200808364B (en) 2010-02-24
US8569294B2 (en) 2013-10-29
KR20080102430A (ko) 2008-11-25

Similar Documents

Publication Publication Date Title
NO20084302L (no) 2-(syklisk amino)-pyrimidonderivater som TPK1-inhibitorer
NO20071787L (no) 2-morfolin-4-pyrimidonforbindelse
NO20072214L (no) 6-(pyridinyl)-4-pyrimidonderivater som inhibitorer av tau-proteinkinase-1
NO20064763L (no) Forbindelser og fremgangsmater for behandling av dyslipidemi
NO20082496L (no) Pyrazinderivater
NO20073791L (no) Pyrazolylaminopyridinderivater anvendbare som kinaseinhibitorer
NO20091889L (no) Inhibitorer av spiroketon acetyl-CoA karboksylase
EA201000050A1 (ru) Замещенные бициклолактамные соединения
NO20081554L (no) Isoindollmidforbindelser og sammensetninger omfattende samme, og anvendelse derav
NO20070258L (no) Benzyltriazolonforbindelser som ikke-nukleoside revers transkriptase inhibitorer
NO20056192L (no) Kapaseinhibitorer og anvendelse derav
NO20083207L (no) Inhibitorer av IAP
NO20072371L (no) Kinuklidinderivater og deres anvendelse som muskarine M3-reseptorantagonister
NO20064351L (no) Caspaseinhibitorer og anvendelser derav
CY1116885T1 (el) Υποκατεστημενα παραγωγα κυκλοεξυλομεθυλιου
NO20075624L (no) Nye histamin H3-reseptorligander og deres terapeutiske anvendelser
NO20092286L (no) Nitrogenhaldige heterosykliske forbindelser og anvendelse derav
NO20081217L (no) Nye benzotiazolonderivater
NO20083708L (no) 4-Fenyl-tiazol-5-karboksylsyre og 4-fenyl-tiazol-5-karboksylmider som PLK1-inhibitorer
ATE543803T1 (de) 3-ä2-(3-azylamino-2-oxo-2h-pyridin-1- yl)acetylaminoü-4-oxopentansäurederivate und deren verwendung als caspase-inhibitoren
DK1723138T3 (da) Substituerede benzimidazoler og deres anvendelse til at inducere apoptose
NO20080394L (no) N-(arylalkyl)-1H-pyrrolopyridin-2-karboksamidderivater, fremstilling og anvendelse derav
DE602004008959D1 (de) Benzoäbüä1,4üdioxepinderivate
NO20076000L (no) Aminosyrederivater
ATE488510T1 (de) Heterocyclische derivate, deren herstellung und therapeutische verwendung

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application